Balance Sheet
Cash Flow Statement
Daily Values
DMA 100DMA 200DMA 50Dividend YieldEV to CFOEV to EBITEV to EBITDAEV to FCFEV to RevenueEnterprise ValueMarket Cap to FCFMarket CapitalizationPricePrice to EarningsPrice to Sales
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Catalyst Pharmaceuticals (CPRX) Enterprise Value (2016 - 2026)

Catalyst Pharmaceuticals filings provide 17 years of Enterprise Value readings, the most recent being -$755.9 million for Q1 2026.

  • On a quarterly basis, Enterprise Value fell 30.17% to -$755.9 million in Q1 2026 year-over-year; TTM through Mar 2026 was -$755.9 million, a 30.17% decrease, with the full-year FY2025 number at -$709.2 million, down 37.02% from a year prior.
  • Enterprise Value hit -$755.9 million in Q1 2026 for Catalyst Pharmaceuticals, down from -$709.2 million in the prior quarter.
  • In the past five years, Enterprise Value ranged from a high of -$121.0 million in Q3 2023 to a low of -$755.9 million in Q1 2026.
  • Median Enterprise Value over the past 5 years was -$310.4 million (2024), compared with a mean of -$387.8 million.
  • Biggest five-year swings in Enterprise Value: surged 53.87% in 2023 and later crashed 276.03% in 2024.
  • Catalyst Pharmaceuticals' Enterprise Value stood at -$298.4 million in 2022, then surged by 53.87% to -$137.6 million in 2023, then crashed by 276.03% to -$517.6 million in 2024, then tumbled by 37.02% to -$709.2 million in 2025, then dropped by 6.58% to -$755.9 million in 2026.
  • The last three reported values for Enterprise Value were -$755.9 million (Q1 2026), -$709.2 million (Q4 2025), and -$689.9 million (Q3 2025) per Business Quant data.